Cell & Gene Therapy

  1. Development Of A Serotype-Agnostic AAV Platform For Suspension Cell Culture 9/4/2025

    To evaluate performance, we compared a suspension process with an adherent iCELLis (200 m²) system, assessing upstream and downstream recovery, as well as analytics using an AAV testing platform.

  2. Lentiviral Vectors: The Key To Cell And Gene Therapy Success 7/30/2025

    Lentiviral vector manufacturing is complex and highly regulated, which is why a specialized CDMO is required to ensure safe, scalable, and compliant production from early development to commercialization.

  3. AAV Viral Titering Using Nanoplate-Based Digital PCR 7/22/2025

    Examine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.

  4. cGMP-Ready Clonal HEK293 Cell Line For AAV, Lenti-, And Adenoviral Vectors 11/7/2024

    See how this advanced SKPT-HEK293 4G9 was able to provide a robust, CGMP-ready solution for efficient viral vector production, supporting a range of AAV serotypes and CAR-T Lenti-viral vectors for scalable manufacturing.

  5. Advancing Viral Vector Manufacturing: The Importance Of The Cell Line 9/16/2024

    Explore the pivotal role of cell lines in viral vector manufacturing, a complex, multi-step process that has traditionally been both time-consuming and labor-intensive.

  6. A Platform Approach To Accelerating Advanced Therapy Development And Manufacturing 9/16/2024

    Explore strategies for integrating cutting-edge technologies and optimizing unit operations to expedite the development and manufacturing of cell and gene therapies.

  7. Development Of A Universal, GMP-Ready, Clonal HEK293 Cell Line 9/16/2024

    When manufacturing adeno-associated virus, lenti- and adenoviral vectors, see how this HEK293 cell line is optimized for suspension culture and viral vector production, which can significantly reduce costs.